Insys Therapeutics, Inc.
INSY
INSY was delisted on the 18th of June, 2019.
124 hedge funds and large institutions have $442M invested in Insys Therapeutics, Inc. in 2016 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 39 increasing their positions, 45 reducing their positions, and 26 closing their positions.
10% less funds holding
Funds holding: 138 → 124 (-14)
13% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 45
26% less capital invested
Capital invested by funds: $595M → $442M (-$152M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
50% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 26
80% less call options, than puts
Call options by funds: $2.74M | Put options by funds: $13.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$11.5M |
| 2 |
FCM
Freshford Capital Management
Rye Brook,
New York
|
+$6.94M |
| 3 |
Goldman Sachs
New York
|
+$5.96M |
| 4 |
Renaissance Technologies
New York
|
+$3.35M |
| 5 |
Millennium Management
New York
|
+$2.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$28.1M |
| 2 |
RCAMU
Rothschild & Co Asset Management US
Stamford,
Connecticut
|
-$6.98M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$6.95M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.36M |
| 5 |
State Street
Boston,
Massachusetts
|
-$5.84M |
INSY Hedge Fund Activity: Q2 2016 in Review
124 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q2 2016, worth a combined $442M — down 26% from $595M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of INSY and 13 opened new positions — a net loss of 13 holders — while 45 trimmed existing stakes and 39 added.
The largest buyer was HealthInvest Partners, opening a new position worth an estimated $11.5M. The largest seller was Janus Henderson Investors US, exiting entirely with an estimated $28.1M sold.
- 124 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q2 2016, down from 138 in Q1 2016.
- Funds reported $442M of Insys Therapeutics, Inc. stock for Q2 2016, down 26% quarter-over-quarter.
- 13 funds opened new Insys Therapeutics, Inc. positions in Q2 2016 and 26 closed out, a net change of -13 holders.
- The largest Insys Therapeutics, Inc. buyer in Q2 2016 was HealthInvest Partners, an estimated $11.5M added.
- The largest Insys Therapeutics, Inc. seller in Q2 2016 was Janus Henderson Investors US, an estimated $28.1M sold.
Based on aggregated 13F filings for Q2 2016.